Nektar Therapeutics drops as jury deliberates in Eli Lilly patent dispute over Rezpeg (NKTR:NASDAQ)
· seekingalpha.com
Nektar (NKTR) stock sank 11% as a jury deliberates its patent dispute with Eli Lilly over Rezpeg
Nektar Therapeutics (NKTR) quickly sank 11% as a jury deliberated in its patent dispute with Eli Lilly (LLY) over its Rezpeg drug.
The jury in San Francisco fe...